YBGJ — Yubo International Biotech Income Statement
0.000.00%
- $15.17m
- $15.29m
- $0.00m
Annual income statement for Yubo International Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 February 29th | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 1.24 | 0.104 | 0.605 | 0.003 |
Cost of Revenue | |||||
Gross Profit | — | 0.821 | 0.053 | 0.419 | 0.003 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.029 | 2.79 | 1.31 | 1.8 | 1.99 |
Operating Profit | -0.029 | -1.54 | -1.21 | -1.19 | -1.98 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -0.134 | -1.54 | -1.2 | -1.2 | -1.98 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.134 | -1.54 | -1.2 | -1.2 | -1.98 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -0.134 | -1.54 | -1.2 | -1.2 | -1.78 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.134 | -1.54 | -1.2 | -1.2 | -1.78 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.114 | -0.013 | -0.01 | -0.01 | -0.013 |